Media headlines about Strongbridge Biopharma (NASDAQ:SBBP) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Strongbridge Biopharma earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.5573840953854 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
SBBP has been the subject of a number of research analyst reports. BidaskClub upgraded Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Zacks Investment Research upgraded Strongbridge Biopharma from a “sell” rating to a “hold” rating in a report on Friday. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price target on shares of Strongbridge Biopharma in a report on Monday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $12.81.
Shares of NASDAQ SBBP opened at $7.60 on Friday. Strongbridge Biopharma has a 12-month low of $3.50 and a 12-month high of $9.25. The firm has a market capitalization of $377.72, a P/E ratio of -5.24 and a beta of 0.99. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.34). The company had revenue of $2.98 million during the quarter, compared to analyst estimates of $2.98 million. analysts forecast that Strongbridge Biopharma will post -1.52 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Strongbridge Biopharma (SBBP) Getting Somewhat Favorable News Coverage, Study Finds” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/strongbridge-biopharma-sbbp-getting-somewhat-favorable-news-coverage-study-finds.html.
About Strongbridge Biopharma
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.